Abstract:Objectives. The human beta(1)-adrenergic receptor, an important therapeutic target in cardiovascular diseases, has 2 common functional polymorphisms (Ser49Gly and Gly389Arg). Our study aimed to confirm that beta(1)-adrenergic receptor polymorphisms affect the blood pressure response to metoprolol monotherapy in the Chinese population with hypertension.Methods. beta(1)-Adrenergic receptor genotype was determined by polymerase chain reaction-restriction fragment length polymorphism assay for 223 patients with essential hypertension. Sixty-one patients with certain beta(1)-adrenergic receptor diplotypes, 18 for 49Ser389Arg/49Ser389Arg, 15 for 49Ser389Arg/49Gly389Arg, 19 for 49Ser389Gly/49Gly389Arg, and 9 for 49Ser389Gly/49Ser389Gly, were selected from those 61 for measurement of the antihypertensive effect of metoprolol. Patients were given 25 mg metoprolol every 12 hours for 4 weeks. Heart rate and blood pressure were measured weekly for the duration of metoprolol therapy.Results The descent of systolic blood pressure after metoprolol administration was significantly different among genotype groups (10.4% +/- 4.0%,2.8% +/- 4.7%, and 1.1% +/- 1.5% for ArgMArg, GlyMArg, and Gly389Gly patients, respectively; P < .001). We also found a similar difference in changes of diastolic blood pressure (6.1% +/- 4.3%, 2.2% +/- 4.20%, and 0.9% +/- 4.0%, respectively, P < .001) and mean arterial pressure (8.1% +/- 3.5%, 2.5% +/- 3.0%, and 1.0% +/- 2.5%, respectively; P > .001) for Arg389Arg, GlyMArg, and Gly389Gly patients. Ser49Gly variance exhibited a smaller contribution to the antihypertensive effect of metoprolol. Systolic blood pressure decreased significantly in Ser49 homozygous patients compared with Ser49Gly patients (8.4% +/- 3.2% versus 5.3% +/- 5.2%, P = .047). There was a highly significant relationship between diplotype and blood pressure during treatment. Systolic blood pressure significantly decreased in 49Ser389Arg/49Ser389Arg (12.0% +/- 3.8%, P < .001) and 49Ser389Arg/49Gly389Arg (8.4% +/- 5.5%, P < .001) patients, with the decrease in the former being more pronounced (P = .023). We also found a significant decrease in diastolic blood pressure (6.5% +/- 4.7% versus 5.7% +/- 3.2%, respectively; both P < .001) and mean arterial pressure (8.8% +/- 3.2% versus 6.9% +/- 3.7%, respectively; both P < .001) in 49Ser389Arg/49Ser389Arg and 49Ser389Arg/49Gly389Arg patients. However, blood pressure did not change significantly in 49Ser389Gly/49Gly389Arg and 49Ser389Gly/49Ser389Gly patients (all P > .05).Conclusions. beta(1)-Adrenergic receptor polymorphism. was associated with different blood pressure responses to metoprolol therapy in patients with essential hypertension. 49Ser389Arg/49Ser389Arg and 49Ser389Arg/49Gly389Arg patients were good responders to metoprolol therapy; 49Ser389Arg/49Ser389Arg patients had a larger systolic blood pressure reduction than 49Ser389Arg/49Gly389Arg patients did. 49Ser389Gly/49Gly389Arg and 49Ser389Gly/49Ser389Gly patients were nonresponders to metoprolol antihypertensive therapy.

eNOS and BDKRB2 genotypes affect the antihypertensive responses to enalapril

Relationship Between Bradykinin B1 Receptor Gene Polymorphism And Antihypertensive Therapy

Effect of NR3C2 genetic polymorphisms on the blood pressure response to enalapril treatment.

Study on the relationship between the therapeutic effect of enalapril on blood pressure reduction and ACE genetic polymorphisms

Single nucleotide polymorphism (SNP) rs4291 of the angiotensin-converting enzyme (ACE) gene is associated with the response to losartan treatment in hypertensive patients

Influence of PRKCH Gene Polymorphism on Antihypertensive Response to Amlodipine and Telmisartan

Angiotensin-converting Enzyme 2 Gene Polymorphism and Long-Term Anti-Hypertensive Effects of Benazepril

Relationship between polymorphisms of renin-angiotensin system gene and pressure-lowering response to irbesartan treatment in hypertension patients

[Correlation of Angiotensin-Converting Enzyme 2 Gene Polymorphism with Antihypertensive Effects of Benazepril].

Interactions of renin-angiotensin system gene polymorphisms and antihypertensive effect of benazepril in Chinese population.

Relationship between polymorphisms in RAS and blood pressure-lowering response to irbesartan in hypertensive patients

Β1-Adrenergic Receptor ( Arg389Gly ) Polymorphism and Response to Bisoprolol in Patients with Chronic Heart Failure

Pharmacogenetic study of CES1 gene and enalapril efficacy

Association Between Angiotensinogen, Angiotensin II Receptor Genes, and Blood Pressure Response to an Angiotensin-Converting Enzyme Inhibitor

Association of Common Polymorphisms in Β1-Adrenergic Receptor with Antihypertensive Response to Carvedilol.

Electrocardiographic left ventricular hypertrophy, β3 adrenergic receptor polymorphism and endpoint of ACEI treatment of hypertension

E112D Polymorphism in the Prolylcarboxypeptidase Gene is Associated with Blood Pressure Response to Benazepril in Chinese Hypertensive Patients.

Association of angiotensin-converting enzyme and endothelial Nitric Oxide synthase gene polymorphisms with vascular disease in ESRD patients in a Chinese population

Effects of Genetic Factors on the Pharmacokinetics and Pharmacodynamics of Amlodipine in Primary Hypertensive Patients.

Arg347Cys polymorphism of |[alpha]|1A-adrenoceptor gene is associated with blood pressure response to nifedipine GITS in Chinese hypertensive patients

Beta(1)-Adrenergic Receptor Polymorphisms Influence The Response To Metoprolol Monotherapy In Patients With Essential Hypertension